Page last updated: 2024-08-17

quinoxalines and Adrenocortical Carcinoma

quinoxalines has been researched along with Adrenocortical Carcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bagby, SM; Kar, A; Kiseljak-Vassiliades, K; Leong, S; Pitts, TM; Saeed, J; Somerset, H; Tompkins, KD; Wierman, ME; Yacob, BW; Zhang, Y	1

Other Studies

1 other study(ies) available for quinoxalines and Adrenocortical Carcinoma

Article	Year
Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocrine-related cancer, 2019, Volume: 26, Issue:10 Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Phosphorylation; Prognosis; Quinoxalines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays	2019

Article

Year

Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.

Endocrine-related cancer, 2019, Volume: 26, Issue:10

Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Phosphorylation; Prognosis; Quinoxalines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays

2019